Your browser doesn't support javascript.
loading
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Nanda, Rita; Liu, Minetta C; Yau, Christina; Shatsky, Rebecca; Pusztai, Lajos; Wallace, Anne; Chien, A Jo; Forero-Torres, Andres; Ellis, Erin; Han, Heather; Clark, Amy; Albain, Kathy; Boughey, Judy C; Jaskowiak, Nora T; Elias, Anthony; Isaacs, Claudine; Kemmer, Kathleen; Helsten, Teresa; Majure, Melanie; Stringer-Reasor, Erica; Parker, Catherine; Lee, Marie C; Haddad, Tufia; Cohen, Ronald N; Asare, Smita; Wilson, Amy; Hirst, Gillian L; Singhrao, Ruby; Steeg, Katherine; Asare, Adam; Matthews, Jeffrey B; Berry, Scott; Sanil, Ashish; Schwab, Richard; Symmans, W Fraser; van 't Veer, Laura; Yee, Douglas; DeMichele, Angela; Hylton, Nola M; Melisko, Michelle; Perlmutter, Jane; Rugo, Hope S; Berry, Donald A; Esserman, Laura J.
Affiliation
  • Nanda R; The University of Chicago, Chicago, Illinois.
  • Liu MC; Mayo Clinic, Rochester, Minnesota.
  • Yau C; University of California, San Francisco.
  • Shatsky R; University of California, San Diego.
  • Pusztai L; Yale University, New Haven, Connecticut.
  • Wallace A; University of California, San Diego.
  • Chien AJ; University of California, San Francisco.
  • Forero-Torres A; University of Alabama, Birmingham.
  • Ellis E; Swedish Cancer Center.
  • Han H; Moffitt Cancer Center, Tampa, Florida.
  • Clark A; University of Pennsylvania, Philadelphia.
  • Albain K; Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
  • Boughey JC; Mayo Clinic, Rochester, Minnesota.
  • Jaskowiak NT; The University of Chicago, Chicago, Illinois.
  • Elias A; University of Colorado, Aurora.
  • Isaacs C; Georgetown University, Washington, DC.
  • Kemmer K; Oregon Health & Science University, Portland.
  • Helsten T; University of California, San Diego.
  • Majure M; University of California, San Francisco.
  • Stringer-Reasor E; University of Alabama, Birmingham.
  • Parker C; The University of Chicago, Chicago, Illinois.
  • Lee MC; Moffitt Cancer Center, Tampa, Florida.
  • Haddad T; Mayo Clinic, Rochester, Minnesota.
  • Cohen RN; The University of Chicago, Chicago, Illinois.
  • Asare S; Quantum Leap Healthcare Collaborative, San Francisco, California.
  • Wilson A; Quantum Leap Healthcare Collaborative, San Francisco, California.
  • Hirst GL; University of California, San Francisco.
  • Singhrao R; University of California, San Francisco.
  • Steeg K; University of California, San Francisco.
  • Asare A; Quantum Leap Healthcare Collaborative, San Francisco, California.
  • Matthews JB; University of California, San Francisco.
  • Berry S; Berry Consultants, LLC.
  • Sanil A; Berry Consultants, LLC.
  • Schwab R; University of California, San Diego.
  • Symmans WF; MD Anderson Cancer Center, Houston, Texas.
  • van 't Veer L; University of California, San Francisco.
  • Yee D; University of Minnesota, Minneapolis.
  • DeMichele A; University of Pennsylvania, Philadelphia.
  • Hylton NM; University of California, San Francisco.
  • Melisko M; University of California, San Francisco.
  • Perlmutter J; Gemini Group, Ann Arbor, Michigan.
  • Rugo HS; University of California, San Francisco.
  • Berry DA; Berry Consultants, LLC.
  • Esserman LJ; University of California, San Francisco.
JAMA Oncol ; 6(5): 676-684, 2020 05 01.
Article in En | MEDLINE | ID: mdl-32053137
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Neoadjuvant Therapy / Antibodies, Monoclonal, Humanized / Programmed Cell Death 1 Receptor Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: JAMA Oncol Year: 2020 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Neoadjuvant Therapy / Antibodies, Monoclonal, Humanized / Programmed Cell Death 1 Receptor Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: JAMA Oncol Year: 2020 Document type: Article